Cambrex Invests in New Analytical Development and Method Validation Laboratory at Its High Point, NC Facility
August 30 2017 - 09:10AM
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small
molecule innovator and generic Active Pharmaceutical Ingredients
(APIs), today announced that it is expanding its High Point, NC
facility with the addition of a new $3.2 million, 11,000 sq. ft.
analytical laboratory. The investment comes in response to growing
customer demand for analytical development and validation services
in support of cGMP products at the clinical stage.
Installation of equipment, including HPLCs, mass
spectrometers and support equipment, will commence in Q3 2017, with
validation and start up anticipated in Q4 2017. As a result of the
expansion, Cambrex will add twelve new analytical development
scientists to the R&D team. The laboratory will be used to
broaden analytical support for customer projects at the High Point
site, and forms part of a strategic plan to support Cambrex’s
global analytical development and method validation needs.
“There is a growing demand in the industry to
better understand and characterize APIs and process intermediates
at the clinical stage,” commented Brian Swierenga, VP, Operations
and Site Director for Cambrex High Point. “This expansion
reinforces Cambrex’s position as a leader in small molecule API
clinical and commercial manufacturing while enabling the
organization to stay ahead of regulatory requirements.”
Cambrex acquired the 35,000 sq. ft. High Point
site, formerly PharmaCore, Inc., in October 2016. At the North
Carolina facility, Cambrex produces complex APIs and intermediates
requiring multi-step synthetic processes in batch sizes from
milligrams to 100kg to support clinical trials from Phase I to
Phase III. The site is licensed with the US Drug Enforcement
Administration (DEA) to manufacture Schedule II to Schedule V
controlled substances. The acquisition enhanced Cambrex’s portfolio
of small molecule API services and complements its large scale,
multi-purpose manufacturing facilities in the US and Europe.
This latest expansion at the facility brings the
investment at the site to over $5 million since the acquisition by
Cambrex, and follows the announcement in May 2017 of an increase in
pilot scale manufacturing capacity at the site.
About CambrexCambrex
Corporation is an innovative life sciences company that provides
products, services and technologies to accelerate the development
and commercialization of small molecule therapeutics. The
Company offers Active Pharmaceutical Ingredients (APIs), advanced
intermediates and enhanced drug delivery products for branded and
generic pharmaceuticals. Development and manufacturing capabilities
include enzymatic biotransformations, high potency APIs, high
energy chemical synthesis and controlled substances. For more
information, please visit www.cambrex.com
Contact:
Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155
Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Mar 2023 to Mar 2024